ProNova is redefining the future of cancer treatment by delivering a lower-cost, smaller, lighter and more energy efficient proton therapy solution without sacrificing today’s most important clinical capabilities.
With more than 1.6 million people to be diagnosed with cancer this year, 320,000 of whom will be potential candidates for proton therapy, a low-cost treatment option is needed. Introducing the ProNova SC360, a no-compromise proton therapy solution that will make proton therapy more accessible to patients and physicians.
Latest funding size
Time since last funding
|about 3 years|